RxDoctor Payments Data

Sajid Ali, MD

Cardiovascular Disease · Houston, TXNPI 1750693248

Payments from drug & device makers

$47,222in general payments, 2019–2025

Across 619 payments — averaging $76.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$15K
  • Novartis$12K
  • Cardinal Health 200 LLC$4K
  • Medtronic$2K
  • Cardiovascular Systems Inc.$1K
  • Boston Scientific$1K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$7,16320%
  • Speaking & faculty fees$4,50012%
  • Travel & lodging$3,69710%
  • Food & beverage$20,60257%
  • Education$950%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott92$15,325
Novartis60$12,020
Cardinal Health 200 LLC4$4,317
Medtronic(2 entities)25$2,026
Cardiovascular Systems Inc.8$1,440
Boston Scientific36$1,174
Philips North America LLC7$1,079
Johnson & Johnson50$1,008
Abiomed6$706
Boehringer Ingelheim23$673
Amgen29$598
Shockwave Medical, Inc10$477
Merck22$410
Angiodynamics, Inc.8$383
AstraZeneca16$371
Actelion Pharmaceuticals US, Inc.16$363
Arbor Pharmaceuticals, Inc.27$358
Baxter Healthcare9$357
Novo Nordisk16$291
Ablative Solutions, Inc.4$289
E.r. Squibb & Sons, L.L.C.14$280
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)14$215
Amarin Pharma, Inc.10$204
Esperion Therapeutics, Inc.11$203
Akcea Therapeutics, Inc.5$200
Cleerly, Inc.8$186
Impulse Dynamics (USA) Inc.2$171
Bard Peripheral Vascular, Inc.3$163
Biotronik Inc.3$160
Lundbeck LLC8$144
Bardy Diagnostics, Inc.3$140
Sanofi-aventis U.S. LLC7$120
Kiniksa Pharmaceuticals, Ltd.4$98
Lexicon Pharmaceuticals, Inc.4$93
Teleflex LLC1$88
Astellas Pharma US Inc4$76
Endologix LLC3$76
Pfizer5$72
Bayer3$66
Scpharmaceuticals Inc.3$64
Edwards Lifesciences3$60
W. L. Gore & Associates, Inc.1$58
Cardiva Medical, Inc.3$58
Azurity Pharmaceuticals, Inc.3$54
Surmodics, Inc.2$50
Kestra Medical Technology Services, Inc.2$46
Althera Pharmaceuticals LLC4$43
Veryan Medical Incorporated1$42
Gilead2$36
BD1$32
Bolton Medical Inc1$30
Innovation Technologies Inc1$29
Irhythm Technologies, Inc.1$25
Tactile Systems Technology Inc1$22
Cashflow Solutions, LLC2$21
Mayne Pharma Commercial LLC1$21
Medicomp Inc1$19
Agepha Pharma FZ LLC1$18
Siemens Medical Solutions USA, Inc.1$17
Lilly USA, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,222 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$166,100
Medicare patients
214
Services billed
1,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban177$175,027
FarxigaDapagliflozin Propanediol133$135,131
EntrestoSacubitril/Valsartan100$121,202
OzempicSemaglutide107$115,896
EliquisApixaban68$80,974
BrilintaTicagrelor57$57,354
JardianceEmpagliflozin29$40,154
Repatha SyringeEvolocumab17$13,725
NexlizetBempedoic Acid/Ezetimibe12$10,954
Wixela InhubFluticasone Propion/Salmeterol52$5,550
Ranolazine ErRanolazine48$3,839
Amiodarone Hcl56$3,822
Nebivolol Hcl37$3,127
Metoprolol Succinate299$3,009
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$2,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$371$192,485190 claims
Johnson & JohnsonXarelto$1,008$175,027177 claims
NovartisEntresto$12,020$121,202100 claims
Novo NordiskOzempic$291$115,896107 claims
PfizerEliquis$72$80,97468 claims
Boehringer IngelheimJardiance$673$40,15429 claims
Esperion Therapeutics, Inc.Nexlizet$203$10,95412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →